Lisa Pham is a Reporter at Bloomberg Law. She covers a diverse range of topics including finance, trading, investment, and energy, with a particular focus on health and wellness themes, such as medicine and alternative medicine. Lisa's work has been featured in prominent publications including Bloomberg Law, The Washington Post, and Fortune.
Preston is the artificial intelligence that powers the Intelligent Relations PR platform. Meet Preston
Not enough data
Lisa Pham's coverage primarily focuses on health and finance, with an emphasis on investment analysis and citing data. To effectively reach out to her, consider offering insights or expert commentary related to the intersection of health and finance such as the impact of healthcare trends on stock markets, emerging opportunities in the pharmaceutical industry, or analyses regarding the financial implications of health-related regulatory changes.
Given that Lisa covers ESG campaigns falling out of favor with activist investors among other topics like obesity drugs and retail, she may be interested in receiving pitches from experts who can provide unique perspectives on evolving consumer trends in these areas. If you have proprietary data or specialized knowledge about how these factors are impacting industries from a financial perspective, it could make for a compelling pitch to Lisa.
This information evolves through artificial intelligence and human feedback. Improve this profile .
By: Angel Adegbesan, Lisa Pham
Die Aktien der Hersteller für Medikamente gegen Fettleibigkeit fuhren 2024 Achterbahn. Die enttäuschenden Studienergebnisse für das experimentelle Adipositas-Mittel CagriSema von Novo Nordisk beenden nun das volatile Jahr.
Membership for the populist Reform UK party has surpassed that of the Conservatives, according to the party led by
Hi, it’s Lisa in London, where I was unfortunately reinfected with Covid recently — a scenario I’d tried to avoid, given its potential to worsen my long Covid condition. But before we get to that...
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025.
Lisa Pham 4 min read In This Article (Bloomberg) -- Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer's disease in 2025.
By: Ishika Mookerjee, William Mathis, Lisa Pham
(Bloomberg) -- Donald Trump’s arrival in the White House is about to revitalize a group of assets long under attack by the Republican Party.Most Read from BloombergThese Homes Withstood the LA Fires. Architects Explain WhyAs E-Bikes Boom in NYC, Some Call for More RegulationsChicago Agency Pitches $1.5 Billion Plan to Fix Transit WoesNYPD Reforms Car Chase Policy Amid Rising Crashes, InjuriesChurches, Cinemas — and Moon Artifacts — Top List of Endangered MonumentsThat’s according to a pair of he
By: Lisa Pham, Kit Rees
LVMH's market cap overtakes Novo for first time since 2023 Earnings from peers, China stimulus hopes help boost sentiment
By: Lisa Pham, Kit Rees
It’s taken LVMH nearly a year-and-a-half to regain its spot as Europe’s biggest stock from Novo Nordisk A/S.
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer’s disease in 2025.
Investors seeking the next obesity-like market opportunity will be closely watching developments related to treatments for Alzheimer's disease in 2025.
(833) 317-6278 
